Use of rituximab in the of immunoinflammatory rheumatic diseases combined with Graves' disease (autoimmune polyglandular syndrome in adults): case report and literature review ; Применение ритуксимаба при сочетании иммуновоспалительных ревматических заболеваний с болезнью Грейвса (аутоиммунным полигландулярным синдромом взрослых): описание случаев и обзор литературы

Συγγραφείς: T. S. Panevin, E. G. Zotkin, Т. С. Паневин, Е. Г. Зоткин

Συνεισφορές: The investigation has not been sponsored., Исследование не имело спонсорской поддержки.

Πηγή: Modern Rheumatology Journal; Том 18, № 5 (2024); 103-106 ; Современная ревматология; Том 18, № 5 (2024); 103-106 ; 2310-158X ; 1996-7012

Θεματικοί όροι: микроскопический полиангиит, Graves' disease, diffuse toxic goiter, systemic lupus erythematosus, systemic scleroderma, microscopic polyangiitis, болезнь Грейвса, диффузный токсический зоб, системная красная волчанка, системная склеродермия

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1646/1525; https://mrj.ima-press.net/mrj/article/view/1646/1534; Трошина ЕА, Свириденко НЮ, Ванушко ВЭ и др. Федеральные клинические рекомендации Российской ассоциации эндокринологов по диагностике и лечению токсического зоба. Клиническая и экспериментальная тиреоидология. 2014; 10(3):8-19.; Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006 May;6(5 Pt 1): 859-66. doi:10.1111/j.1600-6143.2006.01288.x.; Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20 "what do B-cells do?". Clin Immunol. 2005 Dec;117(3):207-13. doi:10.1016/j.clim.2005.08.006. Epub 2005 Sep 19.; Паневин ТС, Зоткин ЕГ, Трошина ЕА, Лукина ГВ. Ритуксимаб в лечении болезни Грейвса и эндокринной офтальмопатии. Возможности и ограничения. Научнопрактическая ревматология. 2023;61(5): 545-553.; Hasselbalch HC. B-cell depletion with rituximab – a targeted therapy for Graves' disease and autoimmune thyroiditis. Immunol Lett. 2003 Jul 3;88(1):85-6. doi:10.1016/s0165-2478(03)00032-4.; Паневин ТС, Зоткин ЕГ, Трошина ЕА. Аутоиммунный полиэндокринный синдром взрослых. Фокус на ревматологические аспекты проблемы. Терапевтический архив. 2023;95(10):881-887.; Ferrari SM, Fallahi P, Ruffilli I, et al. The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): Review of the literature and report of a large series. Autoimmun Rev. 2019 Mar;18(3):287-292. doi:10.1016/j.autrev.2018.10.001. Epub 2019 Jan 11.; El Fassi D, Nielsen CH, Hasselbalch HC, Hegedьs L. The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol. 2006 May; 154(5):623-32. doi:10.1530/eje.1.02140.; El Fassi D, Nielsen CH, Bonnema SJ, et al. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab. 2007 May;92(5):1769-72. doi:10.1210/jc.2006-2388. Epub 2007 Feb 6.; Heemstra KA, Toes RE, Sepers J, et al. Rituximab in relapsing Graves' disease, a phase II study. Eur J Endocrinol. 2008 Nov; 159(5):609-15. doi:10.1530/EJE-08-0084. Epub 2008 Jul 15.; Cheetham TD, Cole M, Abinun M, et al. Adjuvant Rituximab-Exploratory Trial in Young People With Graves Disease. J Clin Endocrinol Metab. 2022 Feb 17;107(3):743-754. doi:10.1210/clinem/dgab763.; Jang SY, Shin DY, Lee EJ, et al. Correlation between TSH receptor antibody assays and clinical manifestations of Graves' orbitopathy. Yonsei Med J. 2013 Jul;54(4):1033-9. doi:10.3349/ymj.2013.54.4.1033.; Karasek D, Cibickova L, Karhanova M, et al. Clinical and immunological changes in patients with active moderate-to-severe Graves' orbitopathy treated with very lowdose rituximab. Endokrynol Pol. 2017;68(5): 498-504. doi:10.5603/EP.a2017.0040. Epub 2017 Jun 29.; Supronik J, Szelachowska M, Kretowski A, Siewko K. Rituximab in the treatment of Graves' orbitopathy: latest updates and perspectives. Endocr Connect. 2022 Nov 25; 11(12):e220303. doi:10.1530/EC-22-0303. Print 2022 Dec 1.; El Fassi D, Banga JP, Gilbert JA, et al. Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol. 2009 Mar;130(3):252-8. doi:10.1016/j.clim.2008.09.007. Epub 2008 Oct 28.; Vannucchi G, Campi I, Bonomi M, et al. Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions. Clin Exp Immunol. 2010 Sep;161(3):436-43. doi:10.1111/j.1365-2249.2010.04191.x.; Chen J, Chen G, Sun H. Intravenous rituximab therapy for active Graves' ophthalmopathy: a meta-analysis. Hormones (Athens). 2021 Jun;20(2):279-286. doi:10.1007/s42000-021-00282-6. Epub 2021 Mar 30.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/1646
https://doi.org/10.14412/1996-7012-2024-5-103-106

New ACR/EULAR 2022 classification criteria for ANCA-associated vasculitis ; Новые классификационные критерии АНЦА-ассоциированных системных васкулитов ACR/EULAR 2022

Συγγραφείς: T. V. Beketova, Т. В. Бекетова

Πηγή: Rheumatology Science and Practice; Vol 61, No 5 (2023); 531-536 ; Научно-практическая ревматология; Vol 61, No 5 (2023); 531-536 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: классификационные критерии, antineutrophil cytoplasmic antibodies, granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, classification criteria, антинейтрофильные цитоплазматические антитела, гранулематоз с полиангиитом, микроскопический полиангиит, эозинофильный гранулематоз с полиангиитом

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3347/2312; Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1): 1-11. doi:10.1002/art.37715; Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990;33(8):1101-1107. doi:10.1002/art.1780330807; Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg – Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094-1100. doi:10.1002/art.1780330806; Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222-227. doi:10.1136/ard.2006.054593; Pierrot-Deseilligny Despujol C, Pouchot J, Pagnoux C, Coste J, Guillevin L. Predictors at diagnosis of a first Wegener’s granulomatosis relapse after obtaining complete remission. Rheumatology (Oxford). 2010;49(11):2181-2190. doi:10.1093/rheumatology/keq244; Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187-192. doi:10.1002/art.1780370206; Schönermarck U, Lamprecht P, Csernok E, Gross WL. Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. Rheumatology (Oxford). 2001;40(2):178-184. doi:10.1093/rheumatology/40.2.178; Unizony S, Villarreal M, Miloslavsky EM, Lu N, Merkel PA, Spiera R, et al.; RAVE-ITN Research Group. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. 2016;75(6):1166-1169. doi:10.1136/annrheumdis-2015-208073; Syed R, Rehman A, Valecha G, El-Sayegh S. Pauci-immune crescentic glomerulonephritis: An ANCA-associated vasculitis. Biomed Res Int. 2015;2015:402826. doi:10.1155/2015/402826; Бекетова ТВ, Фролова НФ, Столяревич ЕС, Волков МЮ, Котенко ОН, Александрова ЕН. Проблемы диагностики и лечения АНЦА-ассоциированных системных васкулитов: в фокусе АНЦА-негативный pauci-иммунный гломерулонефрит. Научно-практическая ревматология. 2016;54(5):543-552. doi:10.14412/1995-4484-2016-543-552; Eisenberger U, Fakhouri F, Vanhille P, Beaufils H, Mahr A, Guillevin L, et al. ANCA-negative pauci-immune renal vasculitis: Histology and outcome. Nephrol Dial Transplant. 2005;20(7):1392-1399. doi:10.1093/ndt/gfh830; Finkielman JD, Lee AS, Hummel AM, Viss MA, Jacob GL, Homburger HA, et al.; WGET Research Group. ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am J Med. 2007;120(7):643.e9-643.e14. doi:10.1016/j.amjmed.2006.08.016; Chen LYC, Mattman A, Seidman MA, Carruthers MN. IgG4-related disease: What a hematologist needs to know. Haematologica. 2019;104(3):444-455. doi:10.3324/haematol.2018.205526; Seeliger B, Sznajd J, Robson JC, Judge A, Craven A, Grayson PC, et al. Are the 1990 American College of Rheumatology vasculitis classification criteria still valid? Rheumatology (Oxford). 2017;56(7):1154-1161. doi:10.1093/rheumatology/kex075; Watts RA, Suppiah R, Merkel PA, Luqmani R. Systemic vasculitis – Is it time to reclassify? Rheumatology (Oxford). 2011;50(4):643-645. doi:10.1093/rheumatology/keq229; Basu N, Watts R, Bajema I, Baslund B, Bley T, Boers M, et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis. 2010;69(10):1744-1750. doi:10.1136/ard.2009.119032; Robson JC, Grayson PC, Ponte C, Suppiah R, Craven A, Judge A, et al.; DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Arthritis Rheumatol. 2022;74(3):393-399. doi:10.1002/art.41986; Suppiah R, Robson JC, Grayson PC, Ponte C, Craven A, Khalid S, et al.; DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Arthritis Rheumatol. 2022;74(3):400-406. doi:10.1002/art.41983; Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A, et al.; DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Arthritis Rheumatol. 2022;74(3):386-392. doi:10.1002/art.41982; Бекетова ТВ. Гранулематоз с полиангиитом, патогенетически связанный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения. Научно-практическая ревматология. 2012;50(6):19-28. doi:10.14412/1995-4484-2012-1288

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3347
https://doi.org/10.47360/1995-4484-2023-531-536

Clinical and immunological variants of ANCA-associated systemic vasculitis: a look at the pulmonary fibrosis in microscopic polyangiitis with anti-myeloperoxidase antibodies and rheumatoid factor. Literature review and own observation ; Клинико-иммунологические варианты АНЦА-ассоциированного системного васкулита: в фокусе интерстициальный фиброз легких при микроскопическом полиангиите с гиперпродукцией антител к миелопероксидазе и ревматоидного фактора. Собственное наблюдение и обзор литературы

Συγγραφείς: T. V. Beketova, O. A. Golovina, A. S. Avdeeva, Т. В. Бекетова, О. А. Головина, А. С. Авдеева

Πηγή: Rheumatology Science and Practice; Vol 61, No 1 (2023); 62-69 ; Научно-практическая ревматология; Vol 61, No 1 (2023); 62-69 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: антитела к циклическому цитруллинированному пептиду, microscopic polyangiitis, anti-myeloperoxidase antibody, pulmonary fibrosis, rheumatoid arthritis, rheumatoid factor, antibodies to cyclic citrullinated peptide, микроскопический полиангиит, антитела к миелопероксидазе, интерстициальный фиброз легких, ревматоидный артрит, ревматоидный фактор

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3279/2259; Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1): 1-11. doi:10.1002/art.37715; Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64(10):3452-3462. doi:10.1002/art.34562; Cornec D, Cornec-Le Gall E, Fervenza FC, Specks U. ANCAassociated vasculitis – Clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol. 2016;12(10):570-579. doi:10.1038/nrrheum.2016.123; Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: Comparison of two independent cohorts. Arthritis Rheum. 2008;58(9):2908-2918. doi:10.1002/art.23800; Бекетова ТВ. Алгоритм диагностики системных васкулитов, ассоциированных с антинейтрофильными цитоплазматическими антителами. Терапевтический архив. 2018;90(5):13-21. doi:10.26442/terarkh201890513-21; Nada AK, Torres VE, Ryu JH, Lie JT, Holley KE. Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. Mayo Clin Proc. 1990;65(6):847-856. doi:10.1016/s0025-6196(12)62575-0; Homma S, Matsushita H, Nakata K. Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides. Respirology. 2004;9(2):190-196. doi:10.1111/j.1440-1843.2004.00581.x; Foulon G, Delaval P, Valeyre D, Wallaert B, Debray MP, Brauner M, et al. ANCA-associated lung fibrosis: Analysis of 17 patients. Respir Med. 2008;102(10):1392-1398. doi:10.1016/j.rmed.2008.04.023; Nozu T, Kondo M, Suzuki K, Tamaoki J, Nagai A. A comparison of the clinical features of ANCA-positive and ANCA-negative idiopathic pulmonary fibrosis patients. Respiration. 2009;77(4):407-415. doi:10.1159/000183754; Hervier B, Pagnoux C, Agard C, Haroche J, Amoura Z, Guillevin L, et al.; French Vasculitis Study Group. Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature. Ann Rheum Dis. 2009;68(3):404-407. doi:10.1136/ard.2008.096131; Tzelepis GE, Kokosi M, Tzioufas A, Toya SP, Boki KA, Zormpala A, et al. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J. 2010;36(1):116-121. doi:10.1183/09031936.00110109; Comarmond C, Crestani B, Tazi A, Hervier B, Adam-Marchand S, Nunes H, et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: A series of 49 patients and review of the literature. Medicine (Baltimore). 2014;93(24):340-349. doi:10.1097/MD.0000000000000217; Huang H, Wang YX, Jiang CG, Liu J, Li J, Xu K, et al. A retrospective study of microscopic polyangiitis patients presenting with pulmonary fibrosis in China. BMC Pulm Med. 2014;14:8. doi:10.1186/1471-2466-14-8; Kagiyama N, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y. Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2015;2(1):e000058. doi:10.1136/bmjresp-2014-000058; Flores-Suárez LF, Ruiz N, Saldarriaga Rivera LM, Pensado L. Reduced survival in microscopic polyangiitis patients with pulmonary fibrosis in a respiratory referral centre. Clin Rheumatol. 2015;34(9):1653-1654. doi:10.1007/s10067-015-2967-1; Watanabe T, Minezawa T, Hasegawa M, Goto Y, Okamura T, Sakakibara Y, et al. Prognosis of pulmonary fibrosis presenting with a usual interstitial pneumonia pattern on computed tomography in patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-related nephritis: A retrospective single-center study. BMC Pulm Med. 2019;19(1):194. doi:10.1186/s12890-019-0969-5; Захарова EB, Яковлев BH, Виноградова OB, Шейх ЖВ, Жидкова НВ, Алексеев ВГ. ANCA-ассоциированные васкулиты с поражением легких и почек: клинико-морфологическая характеристика, лечение, исходы. Клиническая медицина. 2013;91(7):38-43.; Ando M, Miyazaki E, Ishii T, Mukai Y, Yamasue M, Fujisaki H, et al. Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir Med. 2013;107(4):608-615. doi:10.1016/j.rmed.2013.01.006; Alba MA, Flores-Suárez LF, Henderson AG, Xiao H, Hu P, Nachman PH, et al. Interstital lung disease in ANCA vasculitis. Autoimmun Rev. 2017;16(7):722-729. doi:10.1016/j.autrev.2017.05.008; Moon JS, Lee DD, Park YB, Lee SW. Rheumatoid factor false positivity in patients with ANCA-associated vasculitis not having medical conditions producing rheumatoid factor. Clin Rheum. 2018;37(10):2771-2779. doi:10.1007/s10067-017-3902-4; Фролова НФ, Корсакова ЛВ, Столяревич ЕС, Бекетова ТВ. Дебют АНЦА-ассоциированного системного васкулита под маской ревматоидного артрита. Научно-практическая ревматология. 2015;53(6):653-656. doi:10.14412/1995-4484-2015-633-656; Pagnoux C, Seror R, Bérezné A, Rouabhia S, Goulvestre C, Guillevin L. Remittent non-destructive polysynovitis in P-ANCApositive vasculitis patients with anti-CCP antibodies. Joint Bone Spine. 2010;77(6):604-607. doi:10.1016/j.jbspin.2010.02.013; Kamali S, Polat NG, Kasapoglu E, Gul A, Ocal L, Aral O, et al. Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjögren’s syndrome, and Wegener’s granulomatosis. Clin Rheumatol. 2005;24(6):673-676. doi:10.1007/s10067-005-1104-y; Watanabe S, Gono T, Nishina K, Sugitani N, Watanabe E, Yabe H, et al. Rheumatoid factor is correlated with disease activity and inflammatory markers in antineutrophil cytoplasmic antibodyassociated vasculitis. BMC Immunol. 2017;18(1):53. doi:10.1186/s12865-017-0234-8; Nathani D, Barnett MH, Spies J, Pollard J, Wang MX, Kiernan MC. Vasculitic neuropathy: Comparison of clinical predictors with histopathological outcome. Muscle Nerve. 2019;59(6):643-649. doi:10.1002/mus.26431; Martín-Nares E, Zuñiga-Tamayo D, Hinojosa-Azaola A. Prevalence of overlap of antineutrophil cytoplasmic antibody associated vasculitis with systemic autoimmune diseases: An unrecognized example of poliautoimmunity. Clin Rheumatol. 2019;38(1):97-106. doi:10.1007/s10067-018-4212-1; Kısacık B, Önder ME, Sayarlıoğlu M, Onat AM. Symmetric polyarthritis as an initial symptom in granulomatosis with polyangiitis: A report of six cases and review of the literature. Eur J Rheum. 2018;5(3):191-193. doi:10.5152/eurjrheum.2018.17050; Holle JU, Herrmann K, Gross WL, Csernok E. Comparative analy sis of different commercial ELISA systems for the detection of anti-neutrophil cytoplasm antibodies in ANCA-associated vasculitides. Clin Exp Rheumatol. 2012;30(1 Suppl 70):66-69.; Kallenberg CG. Key advances in the clinical approach to ANCAassociated vasculitis. Nat Rev Rheumatol. 2014;10(8):484-493. doi:10.1038/nrrheum.2014.104; Braun MG, Csernok E, Schmitt WH, Gross WL. Incidence, target antigens, and clinical implications of antineutrophil cytoplasmic antibodies in rheumatoid arthritis. J Rheumatol. 1996;23(5):826-830.; Cambridge G, Williams M, Leaker B, Corbett M, Smith CR. Antimyeloperoxidase antibodies in patients with rheumatoid arthritis: Prevalence, clinical correlates, and IgG subclass. Ann Rheum Dis. 1994;53(1):24-29. doi:10.1136/ard.53.1.24; Al-Rubaye M. Anti-neutrophlic cytoplasmic antibody elastase, lactoferrin, cathapsin G, and lysozyme in a sample of Iraqi patients with rheumatoid arthritis. Journal of the Faculty of Medicine Baghdad. 2015;57(1):68-74. doi:10.32007/jfacmedbagdad.571312; Locht H, Skogh T, Wiik A. Characterisation of autoantibodies to neutrophil granule constituents among patients with reactive arthritis, rheumatoid arthritis, and ulcerative colitis. Ann Rheum Dis. 2000;59(11):898-903. doi:10.1136/ard.59.11.898; Бекетова ТВ. Микроскопический полиангиит, ассоциированный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения. Терапевтический архив. 2015;(5):33-46 doi:10.1155/2013/726598; van Schaardenburg D, Lagaay AM, Breedveld FC, Hijmans W, Vandenbroucke JP. Rheumatoid arthritis in a population of persons aged 85 years and over. Br J Rheumatol. 1993;32(2):104-109. doi:10.1093/rheumatology/32.2.104; Shillitoe EJ, Lehner T, Lessof MH, Harrison DF. Immunological features of Wegener’s granulomatosis. Lancet. 1974;1(7852):281-284. doi:10.1016/s0140-6736(74)92594-x; Schirmer JH, Wright MN, Vonthein R, Herrmann K, Nölle B, Both M, et al. Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. Rheumatology (Oxford). 2016;55(1):71-79. doi:10.1093/rheumatology/kev286; McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH. Glucocorticoids and relapse and infection rates in antineutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol. 2012;7(2):240-247. doi:10.2215/CJN.05610611; Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-1594. doi:10.1136/annrheumdis-2016-209133; Насонов ЕЛ, Бекетова ТВ, Ананьева ЛП, Васильев ВИ, Соловьев СК, Авдеева АС. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40. doi:10.14412/1995-4484-2019-3-40; Hoffmann-Vold AM, Maher TM, Philpot EP, Ashrafzadeh A, Barake R, Barsotti S, et al. The identification and management of interstitial lung disease in systemic sclerosis: Evidence-based European consensus statements. Lancet Rheumatol. 2020;2(2): 71-83. doi:10.1016/S2665-9913(19)30144-4; Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 2015;44(4):428-436. doi:10.1016/j.semarthrit.2014.09.002; Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19(3):353-359. doi:10.1111/resp.12214; Lepri G, Avouac J, Airò P, Anguita Santos F, Bellando-Randone S, Blagojevic J, et al. Effects of rituximab in connective tissue disorders related interstitial lung disease. Clin Exp Rheumatol. 2016;34(Suppl 100(5)):181-185.; Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al.; Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708-719. doi:10.1016/S2213-2600(16)30152-7; Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford). 2006;45(8):1005-1008. doi:10.1093/rheumatology/kei211; Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640-646. doi:10.3899/jrheum.121043; Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al.; INBUILD Trial Investigators. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718-1727. doi:10.1056/NEJMoa1908681; Richeldi L, Kolb M, Jouneau S, Wuyts WA, Schinzel B, Stowasser S, et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med. 2020;20(1):3. doi:10.1186/s12890-019-1030-4; Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al.; SENSCIS Trial Investigators. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518-2528. doi:10.1056/NEJMoa1903076; Ананьева ЛП, Авдеев СН, Тюрин ИЕ, Лила АМ, Загребнева АИ, Маслянский АЛ, и др. Хронические фиброзирующие интерстициальные заболевания легких с прогрессирующим фенотипом. Научно-практическая ревматология. 2020;58(6): 631-636. doi:10.47360/1995-4484-2020-631-636

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3279
https://doi.org/10.47360/1995-4484-2023-62-69

Вариант АНЦА-ассоциированного системного васкулита: микроскопический полиангиит. Алгоритм диагностики и лечения на конкретном примере ; The ANCA-associated systemic vasculitis form: microscopic polyangiitis. The algorithm of diagnostics and treatment on a particular example

Συγγραφείς: Krasyukova, E. D., Красюкова, Е. Д.

Πηγή: Сборник статей

Θεματικοί όροι: ANCA-ASSOCIATED VASCULITIS, MICROSCOPIC POLYANGIITIS, АНЦА-АССОЦИИРОВАННЫЕ СИСТЕМНЫЕ ВАСКУЛИТЫ, МИКРОСКОПИЧЕСКИЙ ПОЛИАНГИИТ

Περιγραφή αρχείου: application/pdf

Relation: Актуальные вопросы современной медицинской науки и здравоохранения: Материалы VI Международной научно-практической конференции молодых учёных и студентов, посвященной году науки и технологий, (Екатеринбург, 8-9 апреля 2021): в 3-х т.; http://elib.usma.ru/handle/usma/6512

Διαθεσιμότητα: http://elib.usma.ru/handle/usma/6512

Microscopic polyangiitis: Modern concepts and treatment options ; Микроскопический полиангиит: современные представления и возможности терапии

Συγγραφείς: I. T. Murkamilov, K. A. Aitbaev, V. V. Fomin, I. O. Kudaibergenova, F. A. Yusupov, Zh. A. Murkamilova, T. V. Beketova, И. Т. Муркамилов, К. А. Айтбаев, В. В. Фомин, И. О. Кудайбергенова, Ф. А. Юсупов, Ж. А. Муркамилова, Т. В. Бекетова

Πηγή: Rheumatology Science and Practice; Vol 59, No 5 (2021); 608-614 ; Научно-практическая ревматология; Vol 59, No 5 (2021); 608-614 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: цитостатики, ANCA, microscopic polyangiitis, glomerulonephritis, alveolitis, myeloperoxidase, proteinase 3, glucocorticosteroids, rituximab, cytostatics, АНЦА, микроскопический полиангиит, гломерулонефрит, альвеолит, миелопероксидаза, протеиназа 3, глюкокортикоиды, риуксимаб

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3082/2130; Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi:10.1002/art.37715; Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-1594. doi:10.1136/annrheumdis-2016-209133; Бекетова ТВ. Микроскопический полиангиит, ассоциированный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения. Терапевтический архив. 2015;87(5):33-46.; Nguyen Y, Pagnoux C, Karras A, Quéméneur T, Maurier F, Hamidou M, et al. Microscopic polyangiitis: Clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry. J. Autoimmun. 2020;112:102467. doi:10.1016/j.jaut.2020.102467; Wohlwill F. Über die nur mikroskopisch erkennbare Form der Periarteritis nodosa. Virchows Arch Pathol Anat Physiol. 1923;246:36.; Wainwright J, Davson J. The renal appearances in the microscopic form of periarteritis nodosa. J Pathol Bacteriol. 1950;62(2):189-196. doi:10.1002/path.1700620206; Godman GC, Churg J. Wegener’s granulomatosis: pathology and review of the literature. AMA Arch Pathol. 1954;58(6):533-553.; Savage CO, Winearls CG, Evans DJ, Rees AJ, Lockwood CM. Microscopic polyarteritis: Presentation, pathology and prognosis. Q J Med. 1985;56(220):467-483.; van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet. 1985;1(8426):425-429. doi:10.1016/s0140-6736(85)91147-x; Gross WL, Schmitt WH, Csernok E. ANCA and associated diseases: immunodiagnostic and pathogenetic aspects. Clin Exp Immunol. 1993;91(1):1-12. doi:10.1111/j.1365-2249.1993.tb03345.x; Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an International Consensus Conference. Arthritis Rheum. 1994;37(2):187-192. doi:10.1002/art.1780370206; Семенкова ЕН, Бекетова ТВ, Коган ЕА, Козловская ЛВ, Мухин НА. Современные представления о микроскопическом полиангиите. Терапевтический архив. 1995;67(5):39-41.; Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222-227. doi:10.1136/ard.2006.054593; Chung SA, Seo P. Microscopic polyangiitis. Rheum Dis Clin North Am. 2010;36(3):545-558. doi:10.1016/j.rdc.2010.04.003; Fujimoto S, Uezono S, Hisanaga S, Fukudome K, Kobayashi S, Suzuki K, et al. Incidence of ANCA-associated primary renal vasculitis in the Miyazaki Prefecture: The first population based, retrospective, epidemiologic survey in Japan. Clin J Am Soc Nephrol. 2006;1(5):1016-1022. doi:10.2215/CJN.01461005; Ormerod AS, Cook MC. Epidemiology of primary systemic vasculitis in the Australian Capital Territory and south-eastern New South Wales. Intern Med J. 2008;38(11):816-823. doi:10.1111/j.1445-5994.2008.01672.x; Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70(3):488-494. doi:10.1136/ard.2010.137778; Shi J, Shen Q, Chen XM, Du XG. Clinical characteristics and outcomes in microscopic polyangiitis patients with renal involvement: a study of 124 Chinese patients. BMC Nephrol. 2019;20(1):339. doi:10.1186/s12882-019-1535-3; Sugiyama K, Sada KE, Kurosawa M, Wada J, Makino H. Current status of the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan. Clin Exp Nephrol. 2013;17(1):51-58. doi:10.1007/s10157-012-0651-1; Lane SE, Watts R, Scott DG. Epidemiology of systemic vasculitis. Curr Rheumatol Rep. 2005;7(4):270-275. doi:10.1007/s11926-005-0036-5; Comarmond C, Crestani B, Tazi A, Hervier B, Adam- Marchand S, Nunes H, et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: A series of 49 patients and review of the literature. Medicine (Baltimore). 2014;93(24):340-349. doi:10.1097/MD.0000000000000217; Бекетова ТВ. Алгоритм диагностики системных васкулитов, ассоциированных с антинейтрофильными цитоплазматическими антителами. Терапевтический архив. 2018;90(5):13-21.; Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, et al. Genetically distinct subsets within ANCA-associated vascuonline litis. N Engl J Med. 2012;367(3):214-223. doi:10.1056/NEJMoa1108735; Tsuchiya N, Kobayashi S, Hashimoto H, Ozaki S, Tokunaga K. Association of HLA-DRB1*0901-DQB1*0303 haplotype with microscopic polyangiitis in Japanese. Genes Immun. 2006;7(1):81-84. doi:10.1038/sj.gene.6364262; Rahmattulla C, Mooyaart AL, van Hooven D, Schoones JW, Bruijn JA, Dekkers OM, et al. Genetic variants in ANCAassociated vasculitis: A meta-analysis. Ann Rheum Dis. 2016;75(9):1687-1692. doi:10.1136/annrheumdis-2015-207601; Первакова МЮ, Чудинов АЛ, Лапин СВ, Беляева ИБ, Мазуров ВИ, Блинова ТВ, и др. Диагностическая и клиническая значимость определения фенотипа α-1-антитрипсина при системных васкулитах. Научно-практическая ревматология. 2017;55(2):164-168.; Hagen EC, Ballieux BE, van Es LA, Daha MR, van der Woude FJ. Antineutrophil cytoplasmic autoantibodies: A review of the antigens involved, the assays, and the clinical and possible pathogenetic consequences. Blood. 1993;81(8):1996-2002.; Kallenberg CG, Brouwer E, Weening JJ, Tervaert JW. Antineutrophil cytoplasmic antibodies: Current diagnostic and pathophysiological potential. Kidney Int. 1994;46(1):1-15. doi:10.1038/ki.1994.239; Krumbholz M, Specks U, Wick M, Kalled SL, Jenne D, Meinl E. BAFF is elevated in serum of patients with Wegener’s granulomatosis. J Autoimmun. 2005;25(4):298-302. doi:10.1016/j.jaut.2005.08.004; Witko-Sarsat V, Daniel S, Noël LH, Mouthon L. Neutrophils and B lymphocytes in ANCA-associated vasculitis. APMIS Suppl. 2009;127:27-31. doi:10.1111/j.1600-0463.2009.02473.x; Taekema-Roelvink MEJ, Kooten CV, Kooij SV, Heemskerk E, Daha MR. Proteinase 3 enhances endothelial monocyte chemoattractant protein-1 production and induces increased adhesion of neutrophils to endothelial cells by upregulating intercellular cell adhesion molecule-1. J Am Soc Nephrol. 2001;12(5):932-940. doi:10.1681/ASN.V125932; Mayet WJ, Schwarting A, Meyer zum Büschenfelde KH. Cytotoxic effects of antibodies to proteinase 3 (C-ANCA) on human endothelial cells. Clin Exp Immunol. 1994;97(3):458-465. doi:10.1111/j.1365-2249.1994.tb06110.x; Foucher P, Heeringa P, Petersen AH, Huitema MG, Brouwer E, Tervaert JW, et al. Antimyeloperoxidase-associated lung disease. An experimental model. Am J Respir Crit Care Med. 1999;160(3):987-994. doi:10.1164/ajrccm.160.3.9807139; Xiao H, Heeringa P, Liu Z, Huugen D, Hu P, Maeda N, et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol. 2005;167(1):39-45. doi:10.1016/S0002-9440(10)62951-3; Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol. 2009;20(2):289-298. doi:10.1681/ASN.2008050497; Hao J, Meng LQ, Xu PC, Chen M, Zhao MH. p38MAPK, ERK and PI3K signaling pathways are involved in C5a-primed neutrophils for ANCA-mediated activation. PLoS ONE. 2012;7(5):e38317. doi:10.1371/journal.pone.0038317; Antovic A, Mobarrez F, Manojlovic M, Soutari N, De Porta Baggemar V, Nordin A, et al. Microparticles expressing myeloperoxidase and complement C3a and C5a as markers of renal involvement in antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol. 2020;47(5):714-721. doi:10.3899/jrheum.181347; Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28(9):2756-2767. doi:10.1681/ASN.2016111179; Hu P, Su H, Xiao H, Gou SJ, Herrera CA, Alba MA, et al. Kinin B1 receptor is important in the pathogenesis of myeloperoxidase-specific ANCA GN. J Am Soc Nephrol.2020;31:297-307. doi:10.1681/ASN.2019010032; Yamagata M, Ikeda K, Tsushima K, Iesato K, Abe M, Ito T, et al. Prevalence and responsiveness to treatment of lung abnormalities on chest computed tomography in patients with microscopic polyangiitis: A multicenter, longitudinal, retrospective study of one hundred fifty consecutive hospital-based Japanese patients. Arthritis Rheumatol. 2016;68(3):713-723. doi:10.1002/art.39475; Щеголева ЕМ, Буланов НМ, Виноградова ЕС, Зыкова АС, Новиков ПИ, Моисеев СВ. Варианты течения и исходы микроскопического полиангиита. Клиническая фармакология и терапия. 2018;27(3):35-40.; Hirayama K, Kobayashi M, Usui J, Arimura Y, Sugiyama H, Nitta K, et al. Pulmonary involvements of antineutrophil cytoplasmic autoantibody-associated renal vasculitis in Japan. Nephrol Dial Transplant. 2015;30(Suppl 1):i83-i93. doi:10.1093/ndt/gfu385; Nada AK, Torres VE, Ryu JH, Lie JT, Holley KE. Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. Mayo Clin Proc. 1990;65(6):847-856. doi:10.1016/s0025-6196(12)62575-0; Kida T, Tanaka T, Yokota I, Tamagaki K, Sagawa T, Kadoya M, et al. Association between preexisting lung involvements and the risk of diffuse alveolar hemorrhage in patients with microscopic polyangiitis: A multi-center retrospective cohort study. Mod Rheumatol. 2020;30(2):338-344. doi:10.1080/14397595.2019.1601855; Фролова НФ, Волгина ГВ, Бирюкова ЛС, Столяревич ЕС, Томилина НА. Клинико-морфологические корреляции и прогноз при разных гистоморфологических вариантах быстропрогрессирующего ANCA-ассоциированного гломерулонефрита. Лечебное дело. 2016;4:68-77.; Ahn JK, Hwang JW, Lee J, Jeon CH, Cha HS, Koh EM. Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitides in Korea. Rheumatol Int. 2012;32(10):2979-2986. doi:10.1007/s00296-011-2079-4; Arienti F, Franco G, Monfrini E, Santaniello A, Bresolin N, Saetti MC, et al. Microscopic polyangiitis with selective involvement of Central and Peripheral Nervous System: A case report. Front Neurol. 2020;11:269. doi:10.3389/fneur.2020.00269; Tauseef A, Asghar MS, Amir M, Zafar M, Anum A, Alvi H, et al. Microscopic polyangiitis: An incidental finding in a patient with stroke. J Community Hosp Intern Med Perspect. 2020;10(1):50-54. doi:10.1080/20009666.2020.1718479; Щеголева ЕМ, Зыкова АС, Буланов НМ, Новиков ПИ, Моисеев СВ, Мухин НА. Современные подходы к диагностике и лечению микроcкопического полиангиита. Клиническая медицина. 2018;96(1):66-72.; Фролова НФ, Корсакова ЛВ, Столяревич ЕС, Никонорова НО, Бекетова ТВ. Дебют АНЦА- ассоциированного системного васкулита под маской ревматоидного артрита. Научно-практическая ревматология. 2015;53(6):653-656.; Pagnoux C, Seror R, Bérezné A, Rouabhia S, Goulvestre C, Guillevin L. Remittent non-destructive polysynovitis in P-ANCApositive vasculitis patients with anti-CCP antibodies. Joint Bone Spine. 2010;77(6):604-607. doi:10.1016/j.jbspin.2010.02.013; Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, et al. Microscopic polyangiitis: Clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42(3):421-430. doi:10.1002/1529-0131(199904)42:3 3.0.CO;2-6; Rodgers H, Guthrie JA, Brownjohn AM, Turney JH. Microscopic polyarteritis: Clinical features and treatment. Postgrad Med J. 1989;65(766):515-518. doi:10.1136/pgmj.65.766.515; Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis: Clinical features and mortality. QJM. 2005;98(2):97-111. doi:10.1093/qjmed/hci015; Захарова ЕВ, Яковлев ВН, Виноградова ОВ, Шейх ЖВ, Жидкова НВ, Алексеев ВГ. ANCA-ассоциированные васкулиты с поражением легких и почек: клинико-морфологическая характеристика, лечение, исходы. Клиническая медицина. 2013;91(7):38-42.; Walsh M, Merkel PA, Peh CA, Szpirt WM, Puéchal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med.2020;382(7):622-631. doi:10.1056/NEJMoa1803537; Бекетова ТВ, Насонов ЕЛ. Десятилетний опыт индукционной и поддерживающей терапии ритуксимабом у пациентов с АНЦА-ассоциированными системными васкулитами. Современная ревматология. 2020;14(1):12-19.; Moiseev S, Novikov P, Bulanov N, Zykova A, Safonova E. Assessing cardiovascular risk in patients with antineutrophil cytoplasmic antibody-associated vasculitis: Comment on the article by Wallace et al. Arthritis Rheumatol. 2020;72(1):200-201. doi:10.1002/art.41080; Муркамилов ИТ, Айтбаев КА, Кудайбергенова ИО, Фомин ВВ, Юсупов ФА. Микроскопический полиангиит: диагностические и терапевтические подходы к лечению (обзор литературы и описание клинического случая). The Scientific Heritage.2020;48-2:26-34.; Бекетова ТВ. Перспективные направления терапии систем- ных васкулитов: в фокусе авакопан, пероральный ингибитор С5а рецептора. Клиническая фармакология и терапия. 2019;28(1):75-79.

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3082
https://doi.org/10.47360/1995-4484-2021-608-614

The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic ; Течение и исходы COVID-19 у пациентов с АНЦА-ассоциированными системными васкулитами, получающих лечение генно-инженерными биологическими препаратами (ритуксимаб, меполизумаб): итоги первых 8 месяцев пандемии

Συγγραφείς: T. V. Beketova, V. V. Babak, M. D. Suprun, Т. В. Бекетова, В. В. Бабак, М. Д. Супрун

Συνεισφορές: Работа выполнена в рамках научной темы рег. № НИОКТР АААА-А19-119021190148-3

Πηγή: Rheumatology Science and Practice; Vol 59, No 1 (2021); 37-46 ; Научно-практическая ревматология; Vol 59, No 1 (2021); 37-46 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: эозинофильный гранулематоз с полиангиитом, Rituximab, Mepolizumab, В-cells, interleukin-5, ANCA-associated vasculitis, granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, ритуксимаб, меполизумаб, В-клетки, интерлейкин-5, АНЦА-ассоциированный системный васкулит, гранулематоз с полиангиитом, микроскопический полиангиит

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2988/2056; https://rsp.mediar-press.net/rsp/article/view/2988/2057; Насонов ЕЛ, Лила АМ, Мазуров ВИ, Белов БС, Каратеев АЕ, Дубинина ТВ и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные (аутоиммунные) ревматические заболевания. Проект рекомендаций Общероссийской общественной организации «Ассоциация ревматологов России». 2020 URL: https://rheumatolog.su/news/koronavirusnaya-bolezn-2019-COVID-19-i-immunovospalitelnye-autoimmunnye-revmaticheskie-zabolevaniya/ (accessed: 2020); Бекетова ТВ. Алгоритм диагностики системных васкулитов, ассоциированных с антинейтрофильными цитоплазматическими антителами. Терапевтический архив. 2018;5:13–21 doi:10.26442/terarkh201890513-21; Fornasari PM. COVID-19: Neutrophils “unfriendly fire” imbalance proteolytic cascades triggering clinical worsening and viral sepsis. Potential role explanation for convalescent plasma as “fire hose”. Preprints. 2020;2020050373. doi:10.20944/preprints202005.0373.v1; Luqmani R, Suppiah R, Edwards CJ, Phillip R, Maskell J, Culliford D, et al. Mortality in Wegener’s granulomatosis: A bimodal pattern. Rheumatology (Oxford, England). 2011;50(4): 697–702. doi:10.1093/rheumatology/keq351; Colling ME, Kanthi Y. COVID-19-associated coagulopathy: An exploration of mechanisms. Vascular Medicine. 2020;25(5):471– 478. doi:10.1177/1358863X20932640; Ciceri F, Beretta L, Scandroglio AM, Colombo S, Landoni G, Ruggeri A, et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): An atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc. 2020;22(2):95–97.; Насонов ЕЛ, Бекетова ТВ, Решетняк ТМ, Лила АМ, Ананьева ЛП, Лисицина ТА и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания: на перекрестке проблем тромбовоспаления и аутоиммунитета. Научно-практическая ревматология. 2020;58(4):353–367. doi:10.47360/1995-4484-2020-353-367; Забозлаев ФГ, Кравченко ЭВ, Галлямова АР, Летуновский НН. Патологическая анатомия легких при новой коронавирусной инфекции (COVID-19). Предварительный анализ аутопсийных исследований. Клиническая практика. 2020;11(2):21–37. doi:10.17816/clinpract34849; Kronbichler A, Lee KH, Denicolò S, Choi D, Lee H, Ahn D, et al. Immunopathogenesis of ANCA-associated vasculitis. Int J Mol Sci. 2020;21(19):7319. doi:10.3390/ijms21197319; Talotta R, Robertson E. Autoimmunity as the comet tail of COVID-19 pandemic. World J Clin Cases. 2020;8(17):3621– 3644. doi:10.12998/wjcc.v8.i17.3621; Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020;71(16):2027–2034. doi:10.1093/cid/ciaa344; Woodruff MC, Ramonell RP, Cashman KS, Nguyen DC, Saini AS, Haddad N, et al. Critically ill SARS-CoV-2 patients display lupus-like hallmarks of extrafollicular B cell activation. medRxiv. 2020.04.29.20083717; doi:10.1101/2020.04.29.20083717; Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol. 2020;20:339–341. doi:10.1038/s41577-020-0321-6; Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest. 2020;130(10):5235–5344. doi:10.1172/JCI138759; Sun B, Feng Y, Mo X, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):940–948. doi:10.1080/22221751.2020.1762515; Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585. doi:10.1126/science.abd4585; Song WC, FitzGerald GA. COVID-19, microangiopathy, hemostatic activation, and complement. J Clin Invest. 2020;130(8): 3950–3953. doi:10.1172/JCI140183; Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res. 2020;(220):1–13. doi:10.1016/j.trsl.2020.04.007; Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y, Jia Z, et al. Heightened Innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe. 2020;27:883–890.e2 doi:10.1016/j.chom.2020.04.017; Singh A, Sood N, Narang V, Goyal A. Morphology of COVID-19-affected cells in peripheral blood film. BMJ Case Rep. 2020;13(5):e236117. doi:10.1136/bcr-2020-236117; Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–535. doi:10.1038/s41423-020-0402-2; Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol 2020;20:269–270. doi:10.1038/S41577-020-0308-3; Sachdeva M, Gianotti R, Shah M, Bradanini L, Tosi D, Veraldi S, et al. Cutaneous manifestations of COVID-19: Report of three cases and a review of literature. J Dermatol Sci. 2020;98:75–81. doi:10.1016/j.jdermsci.2020.04.011; Conde Cardona G, Quintana Pájaro LD, Quintero Marzola ID, Ramos Villegas Y, Moscote Salazar LR. Neurotropism of SARS-CoV-2: Mechanisms and manifestations. J Neurol Sci. 2020;412:116824. doi:10.1016/j.jns.2020.116824; Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: Causality or coincidence? Lancet Neurol. 2020;19:383–384. doi:10.1016/S1474-4422(20)30109-5; Lazarian G, Quinquenel A, Bellal M, Siavellis J, Jacquy C, Re D, et al. Autoimmune haemolytic anaemia associated with COVID-19 infection. Br J Haematol. 2020;190:29–31. doi:10.1111/bjh.16794; Zulfiqar AA, Lorenzo-Villalba N, Hassler P, Andrès E. Immune thrombocytopenic purpura in a patient with Covid-19. N Engl J Med. 2020;382:e43. doi:10.1056/NEJMc2010472; Beydon M, Chevalier K, Al Tabaa O, Hamroun S, Delettre AS, Thomas M, et al. Myositis as a manifestation of SARS-CoV-2. Ann Rheum Dis. Published Online First. 2020. doi:10.1136/annrheumdis-2020-217573; Craver R, Huber S, Sandomirsky M, McKenna D, Schieffelin J, Finger L. Fatal eosinophilic myocarditis in a healthy 17-year-old male with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2c). Fetal Pediatr Pathol. 2020;39:263–268. doi:10.1080/1551 3815.2020.1761491; Andina D, Noguera-Morel L, Bascuas-Arribas M, Gaitero-Tristán J, Alonso-Cadenas JA, Escalada-Pellitero S, et al. Chilblains in children in the setting of COVID-19 pandemic. Pediatr Dermatol. 2020;37:406–411. doi:10.1111/pde.14215; Licciardi F, Pruccoli G, Denina M, Parodi E, Taglietto M, Rosati S, et al. SARS-CoV-2-induced Kawasaki-like hyperinflammatory syndrome: A novel COVID phenotype in children. Pediatrics. 2020;146:e20201711. doi:10.1542/peds.2020-1711; Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study. Lancet. 2020;395:1771–1778. doi:10.1016/S0140-6736(20)31103-X; Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol. 2020;16(8):413–414. doi:10.1038/s41584-020-0448-7; Letellier A, Gibelin A, Voiriot G, Fartoukh M, Djibré M. Destructive pulmonary fibrosis after severe COVID-19 pneumonia. Int J Infect Dis. 2020;100:377–378. doi:10.1016/j.ijid.2020.09.026; Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. doi:10.1016/j.clim.2020.108393; Guisado-Vasco P, Valderas-Ortega S, Carralón-González MM, Roda-Santacruz A, González-Cortijo L, Sotres-Fernández G, et al. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). EClinicalMedicine. 2020;28:100591. doi:10.1016/j.eclinm.2020.100591; Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, et al. Eculizumab treatment in patients with COVID-19: Preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24(7):4040–4047. doi:10.26355/eurrev_202004_20875; Насонов ЕЛ, Бекетова ТВ, Ананьева ЛП, Васильев ВИ, Соловьев СК, Авдеева АС. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57(Прил. 1): 3–40. doi:10.14412/1995-4484-2019-3-40; Izquierdo JL, Almonacid C, González Y, Del Rio-Bermúdez C, Ancochea J, Cárdenas R, et al. The impact of COVID-19 on patients with asthma. Eur Respir J. Published online ahead of print. 2020 Dec 17;2003142. doi:10.1183/13993003.03142-2020; Matucci A, Caminati M, Vivarelli E, Vianello A, Micheletto C, Menzella F, et al. COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey. Allergy. 2020. doi:10.1111/all.14516; Banerjee S, George M, Young K, Venkatachalam S, Gordon J, Burroughs C, et al. Effects of the COVID-19 pandemic on patients living with vasculitis. ACR Open Rheumatology. 2020:1–8. doi:10.1002/acr2.11204; Kant S, Morris A, Ravi S, Floyd L, Gapud E, Antichos B, et al. The impact of COVID-19 pandemic on patients with ANCA associated vasculitis. J Nephrol. 2020 Oct 8:1–6. doi:10.1007/s40620-020-00881-3; Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019;4:e123158. doi:10.1172/jci.insight.123158; Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps (NETs) as markers of disease severity in COVID-19. medRxiv. 2020:2020.04.09.20059626. doi:10.1101/2020.04.09.20059626; Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2020;217:108480. doi:10.1016/j.clim.2020.108480; Quinti I, Lougaris V, Cinzia Milito C, Cinetto F, Pecoraro A, Mezzaroma I, et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. J All Clin Immunol. 2020;146(1):211–213.e4. doi:10.1016/j.jaci.2020.04.013; Soresina A, Moratto D, Chiarini M, Paolillo C, Baresi G, Focà E, et al. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol. 2020;31(5):565–569. doi:10.1111/pai.13263; Fill L, Hadney L, Graven K, Persaud R, Hostoffer R. The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019. Ann Allergy Asthma Immunol. 2020;125(1):112–114. doi:10.1016/j.anai.2020.04.033; Montero-Escribano P, Matías-Guiu J, Gómez-Iglesias P, Porta-Etessam J, Pytel V, Matias-Guiu JA. Anti-CD20 and Covid-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain. Mult Scler Relat Disord. 2020;42:102185. doi:10.1016/j.msard.2020.102185; Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord. 2020;43:102195. doi:10.1016/j.msard.2020.102195; Schramm MA, Venhoff N, Wagner D, Thiel J, Huzly D, Craig-Mueller N, et al. COVID-19 in a severely immunosuppressed patient with life-threatening eosinophilic granulomatosis with polyangiitis. Front Immunol. 2020;11:2086. doi:10.3389/fimmu.2020.02086; Suárez-Díaz S, Morán-Castaño C, Coto-Hernández R, et al. Mild COVID-19 in ANCA-associated vasculitis treated with rituximab. Ann Rheum Dis. Published Online First. 2020 Aug 7 doi:10.1136/annrheumdis-2020-218246; Fallet B, Kyburz D, Walker UA. Mild course of Coronavirus disease 2019 and spontaneous severe acute respiratory syndrome coronavirus 2 clearance in a patient with depleted peripheral blood B-cells due to treatment with rituximab. Arthritis Rheumatol. 2020;72:1581–1582. doi:10.1002/art.41380; Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, Thibault A, et al. Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: Lessons from a case with severe pneumonia. Ann Rheum Dis. 2021;80:e10. doi:10.1136/annrheumdis-2020-217549; Loarce-Martos J, García-Fernández A, López-Gutiérrez F, García-García V, Calvo-Sanz L, del Bosque-Granero I, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: A descriptive study. Rheumatol Int. 2020;40(12):2015–2021. doi:10.1007/s00296-020-04699-x; Favalli EG, Agape E, Caporali R. Incidence and clinical course of COVID-19 in patients with connective tissue diseases: A descriptive observational analysis. J Rheumatol. 2020;47:1296. doi:10.3899/jrheum.200507

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2988
https://doi.org/10.47360/1995-4484-2021-37-46

Review of guideline for the management of ANCA-associated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis Foundation ; Обзор рекомендаций по лечению АНЦА-ассоциированных системных васкулитов, представленных в 2021 г. Американской коллегией ревматологов и Фондом васкулитов

Συγγραφείς: T. V. Beketova, I. Yu. Popov, V. V. Babak, Т. В. Бекетова, И. Ю. Попов, В. В. Бабак

Πηγή: Rheumatology Science and Practice; Vol 59, No 6 (2021); 684-692 ; Научно-практическая ревматология; Vol 59, No 6 (2021); 684-692 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: ритуксимаб, antineutrophil cytoplasmic antibodies, granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, rituximab, антинейтрофильные цитоплазматические антитела, гранулематоз с полиангиитом, микроскопический полиангиит, эозинофильный гранулематоз с полиангиитом

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3102/2146; Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73(8):1366-1383. doi:10.1002/art.41773; Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Toumelin PL; French Vasculitis Study Group (FVSG). The Five-Factor Score revisited: Assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90(1):19-27. doi:10.1097/MD.0b013e318205a4c6; Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al.; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232. doi:10.1056/NEJMoa0909905; Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al.; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211-220. doi:10.1056/NEJMoa0909169; Kahn JE, Grandpeix-Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F, et al. Sustained response to mepolizumab in refractory Churg - Strauss syndrome. J Allergy Clin Immunol. 2010;125(1):267-270. doi:10.1016/j.jaci.2009.10.014; Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921-1932. doi:10.1056/NEJMoa1702079; Menditto VG, Rossetti G, Olivari D, Angeletti A, Rocchi M, Gabrielli A, et al. Rituximab for eosinophilic granulomatosis with polyangiitis: A systematic review of observational studies. Rheumatol. 2021;60:1640-1650. doi:10.1093/rheumatology/keab046; Akiyama M, Kaneko Y, Takeuchi T. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: A systematic literature review. Autoimmun Rev. 2021;20:102737. doi:10.1016/j.autrev.2020.102737; Walsh M, Merkel PA, Peh CA, Szpirt WM, Putehal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382:622-631. doi:10.1056/NEJMoa1803537; Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180-2188. doi:10.1681/ASN.2007010090; Walsh M, Casian A, Flossmann O, Westman K, Hoglund P, Pusey C, et al.; European Vasculitis Study Group (EUVAS). Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 2013;84(2):397-402. doi:10.1038/ki.2013.131; Teixeira V, Mohammad AJ, Jones RB, Smith R, Jayne D. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open. 2019;5(1):e000905. doi:10.1136/rmdopen-2019-000905; Crickx E, Machelart I, Lazaro E, Kahn JE, Cohen-Aubart F, Martin T, et al. Intravenous immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vas-culitides: A French nationwide study of ninety-two patients. Arthritis Rheumatol. 2016;68:702-712. doi:10.1002/art.39472; De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:2461-2469. doi:10.1002/art.21142; Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771-1780. doi:10.1056/NEJMoa1404231; Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790-2803. doi:10.1056/NEJMoa0802311; Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial. JAMA. 2010;304:2381-2388. doi:10.1001/jama.2010.1658; Puéchal X, Pagnoux C, Baron G, Quémeneur T, Néel A, Agard C, et al. Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg - Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: A randomized, controlled trial. Arthritis Rheumatol. 2017;69:2175-2186. doi:10.1002/art.40205; Metzler C, Miehle N, Manger K, Iking-Konert C, de Groot K, Hellmich B, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford). 2007;46:1087-1091. doi:10.1093/rheumatology/kem029; Kado R, Sanders G, McCune WJ. Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy (review). Curr Opin Rheumatol. 2017;29:228-233. doi:10.1097/BOR.0000000000000377; Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198-1207. doi:10.1056/NEJMoa1403290; Joshi L, Tanna A, McAdoo SP, Medjeral-Thomas N, Taylor SR, Sandhu G, et al. Long-term outcomes of rituximab therapy in ocular granulomatosis with polyangiitis: Impact on localized and nonlocalized disease. Ophthalmology. 2015;122:1262-1268. doi:10.1016/j.ophtha.2015.01.016; Durel CA, Hot A, Trefond L, Aumaitre O, Pugnet G, Samson M, et al. Orbital mass in ANCA-associated vasculitides: Data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients. Rheumatology (Oxford). 2019;58:1565-1573. doi:10.1093/rheumatology/Kez071; Girard C, Charles P, Terrier B, Bussonne G, Cohen P, Pagnoux C, et al. Tracheobronchial stenoses in granulomatosis with polyangiitis (Wegener's): A report on 26 cases. Medicine (Baltimore). 2015;94:e1088. doi:10.1097/MD.0000000000001088; Sagmeister MS, Grigorescu M, Schonermarck U. Kidney transplantation in ANCA-associated vasculitis. J Nephrol. 2019;32:919-926. doi:10.1007/s40620-019-00642-x; Geetha D, Eirin A, True K, Valentina Irazabal M, Specks U, Seo P, et al. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: A multicenter experience. Transplantation. 2011;91:1370-1375. doi:10.1097/TP.0b013e31821ab9aa; Sachse F, Stoll W. Nasal surgery in patients with systemic disorders. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2010;9:Doc02. doi:10.3205/cto000066; Congdon D, Sherris DA, Specks U, McDonald T. Long-term follow-up of repair of external nasal deformities in patients with Wegener's granulomatosis. Laryngoscope. 2002;112:731-737. doi:10.1097/00005537-200204000-00025; Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis - A meta-analysis. Rheumatology (Oxford). 2012;51(1):100-109. doi:10.1093/rheumatology/ker280; Charles P, Terrier B, Perrodeau E, Cohen P, Faguer S, Huart A, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77:1143-1149. doi:10.1136/annrheumdis-2017-212878

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3102
https://doi.org/10.47360/1995-4484-2021-684-692

Successful total hip arthroplasty in patients with anca-associated systemic vasculitis ; Успешное эндопротезирование тазобедренных суставов у пациентов с АНЦА-ассоциированными системными васкулитами

Συγγραφείς: T. V. Beketova, E. A. Naryshkin, E. V. Arsenyev, M. A. Makarov, Т. В. Бекетова, Е. А. Нарышкин, Е. В. Арсеньев, М. А. Макаров

Πηγή: Rheumatology Science and Practice; Vol 57, No 5 (2019); 597-603 ; Научно-практическая ревматология; Vol 57, No 5 (2019); 597-603 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: эозинофильный гранулематоз с полиангиитом Черджа–Стросс, aseptic necrosis, rituximab, antineutrophil cytoplasmic antibody-associated systemic vasculitis, Wegener’s granulomatosis, microscopic polyangiitis, eosinophilic granulomatosis polyangiitis (or ChurgStrauss syndrome), асептический некроз, ритуксимаб, системные васкулиты, ассоциированные с антинейтрофильными цитоплазматическими антителами, гранулематоз с полиангиитом Вегенера, микроскопический полиангиит

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2784/1888; Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-94. doi:10.1136/annrheumdis-2016-209133; Goodman SM, Springer B, Guyatt G, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Rheum. 2017;69(8):1538-51. doi:10.1002/art.40149; Павлов ВП, Макаров СА, Храмов АЭ. Тотальное эндопротезирование коленного и тазобедренного сустава у пациентов широкого спектра ревматических заболеваний. Медицина (Казахстан). 2014;(10):36-40.; Luqmani R, Bacon P, Moots R, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87(11):671-8.; Guillevin L, Pagnoux C, Seror R, et al; French Vasculitis Study Group (FVSG). The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011 Jan;90(1):19-27. doi:10.1097/MD.0b013e318205a4c6; Bhamra K, Luqmani R. Damage assessment in ANCA-associated vasculitis. Curr Rheumatol Rep. 2012 Dec;14(6):494-500. doi:10.1007/s11926-012-0291-1; Harris WH. Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An end-result study using a new method of result evaluation. J Bone Joint Surg Am. 1969;51:737-55. doi:10.2106/00004623-196951040-00012; Somayaji R, Barnabe C, Martin L. Risk factors for infection following total joint arthroplasty in rheumatoid arthritis. Open Rheumatol J. 2013;7:119-24. doi:10.2174/1874312920131210005; Danoff JR, Moss C, Liabaud B, Geller JA. Total knee arthroplasty considerations in Rheumatoid Arthritis. Autoimmun Dis. 2013;2013:Article ID 185340, 6 p. doi:10.1155/2013/185340 36; Храмов АЭ, Макаров МА, Бялик ЕИ и др. Проблемы диагностики, профилактики и лечения перипротезной инфекции у больных ревматическими заболеваниями. Научно-практическая ревматология. 2015;53(5):558-63. doi:10.14412/1995-4484-2015-558-563; McGregor JG, Hogan SL, Hu Y, et al. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol. 2012;7(2):240-7. doi:10.2215/CJN.05610611; Белов БС, Макаров СА, Бялик ЕИ. Бактериальный (септический) артрит и инфекция протезированного сустава. Научно-практическая ревматология. 2017;55(2):192-200. doi:10.14412/1995-4484-2017-192-200; Lohmann C, Nuechtern J, Junk-Jantsch S, et al. Hypersensitivity reactions in total hip arthroplasty. Orthopedics. 2007;30. doi:10.3928/01477447-20070901-12; Павлов ВП, Вардикова ГН, Макаров СА и др. Эндопротезирование коленного и тазобедренного суставов у больных ревматическими заболеваниями пожилого и старческого возраста. Научно-практическая ревматология. 2003;41(4):101-5. doi:10.14412/1995-4484-2003-1346; Ravi B, Croxford R, Hollands S, et al. Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis. Arthritis Rheum. 2014;66:254-63. doi:10.1002/art.38231; Lin JA, Liao CC, Lee YJ, et al. Adverse outcomes after major surgery in patients with systemic lupus erythematosus: a nationwide population-based study. Ann Rheum Dis. 2014;73:1646-51. doi:10.1136/annrheumdis-2012-202758; Singh JA, Inacio MC, Namba RS, Paxton EW. Rheumatoid arthritis is associated with higher ninety-day hospital readmission rates compared to osteoarthritis after hip or knee arthroplasty: a cohort study. Arthritis Care Res (Hoboken). 2015;67:718-24. doi:10.1002/acr.22497; Roberts JE, Mandl LA, Su EP, et al. Patients with systemic lupus erythematosus have increased risk of short-term adverse events after total hip arthroplasty. J Rheumatol. 2016;43:1498-502. doi:10.3899/jrheum.151373; Kurtz SM, Lau E, Watson H, et al. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty. 2012;Suppl 27:61-5. doi:10.1016/j.arth.2012.02.022; Бекетова ТВ, Александрова ЕН, Новоселова ТМ и др. Российский опыт применения моноклональных антител к В-лимфоцитам (ритуксимаб) при системных васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами (предварительные результаты российского регистра НОРМА). Научно-практическая ревматология. 2014;52(2):147-58. doi:10.14412/1995-4484-2014-147-158; Рыбников АВ, Бялик EИ, Решетняк ТМ и др. Профилактика венозных тромбоэмболий и риск развития послеоперационных осложнений у пациентов с ревматоидным артритом и остеоартритом при эндопротезировании тазобедренного сустава. Научно-практическая ревматология. 2018;56(6):797-804. doi:10.14412/1995-4484-2018-797-804; Mochizuki T, Ikari K, Yano K, et al. Outcome of direct oral anticoagulant treatment for acute lower limb deep venous thrombosis after total knee arthroplasty or total hip arthroplasty. Mod Rheumatol. 2018;1:1-5. doi:10.1080/14397595.2018.1504396; Januel JM, Romano PS, Couris CM, et al. Clinical and health system determinants of venous thromboembolism event rates after hip arthroplasty: An international comparison. International Methodology Consortium for Coded Health Information (IMECCHI). Med Care. 2018;56(10):862-9. doi:10.1097/MLR.000000000000095; Johanson N, Lachiewicz PF, Licbcrman JR, et al. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroscopy. J Am Acad Orthop Surg. 2009;17(17):183-96. doi:10.2106/JBJS.I.00511; D’Angelo A, Kluft C, Verheijen J, et al. Fibrinolytic shut down after surgery: impairment of the balance between tissue-type plasminogen activator and its specific inhibitor. Eur J Clin Invest. 1985;15:308-12 doi:10.1111/j.1365-2362.1985.tb00277; Zoller B, Li X, Sundquist J, Sundquist K. Autoimmune diseases and venous thromboembolism: a review of the literature. Am J Cardiovasc Dis. 2012;2(3):171-83.; Bautz DJ, Preston GA, Lionaki S, et al. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol. 2008 Dec;19(12):2421-9. doi:10.1681/ASN.2008030270; Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. Semin Thromb Hemost. 2019 Feb;45(1):86-93. doi:10.1055/s-0038-1677040; Maino A, Rossio R, Cugno M, et al. Hypereosinophilic syndrome, Churg-Strauss syndrome and parasitic diseases: possible links between eosinophilia and thrombosis. Curr Vasc Pharmacol. 2012 Sep;10(5):670-5. doi:10.2174/157016112801784594; Ames PR, Margaglione M, Mackie S, Alves JD. Eosinophilia and thrombophilia in churg strauss syndrome: a clinical and pathogenetic overview. Clin Appl Thromb Hemost. 2010 Dec;16(6):628-36. doi:10.1177/1076029609348647; Morgan MD, Turnbull J, Selamet U, et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum. 2009 Nov;60(11):3493-500. doi:10.1002/art.24957; Allenbach Y, Seror R, Pagnoux C, et al; French Vasculitis Study Group. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis. 2009 Apr;68(4):564-7. doi:10.1136/ard.2008.099051; Hilhorst M, Winckers K, Wilde B, et al. Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable. J Rheumatol. 2013 Dec;40(12):2042-6. doi:10.3899/jrheum.130200; Stone JH, Merkel PA, Spiera R, et al; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3):221-32. doi:10.1056/NEJMoa0909905

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2784
https://doi.org/10.14412/1995-4484-2019-597-603

THE 2016 EUROPEAN (EULAR/ERA-EDTA) RECOMMENDATIONS FOR THE DIAGNOSIS AND MANAGEMENT OF ANCA-ASSOCIATED SYSTEMIC VASCULITIS ; Европейские (EULAR/ERA-EDTA) рекомендации по диагностике и лечению АНЦА-ассоциированных системных васкулитов – 2016

Συγγραφείς: T. V. Beketova, Т. В. Бекетова

Πηγή: Rheumatology Science and Practice; Vol 55, No 1 (2017); 12-16 ; Научно-практическая ревматология; Vol 55, No 1 (2017); 12-16 ; 1995-4492 ; 1995-4484 ; 10.14412/rjtao20171

Θεματικοί όροι: ритуксимаб, antineutrophil cytoplasmic antibodies, granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, rituximab, антинейтрофильные цитоплазматические антитела, гранулематоз с полиангиитом (Вегенера), микроскопический полиангиит, эозинофильный гранулематоз с полиангиитом

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2332/1537; Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Jun 23. pii: annrheumdis- 2016-209133. doi:10.1136/annrheumdis-2016-209133; Aasarod K, Bostad L, Hammerstrom J, et al. Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis. Nephrol Dial Transplant. 2001;16:953-60. doi:10.1093/ndt/16.5.953; Schnabel A, Holl-Ulrich K, Dalhoff K, et al. Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir J. 1997;10:2738-43. doi:10.1183/09031936.97.10122738; Corapi KM, Chen JL, Balk EM, et al. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis. 2012;60:62-73. doi:10.1053/j.ajkd.2012.02.330; De Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized rial. Ann Intern Med. 2009;150:670-80. doi:10.7326/0003-4819-150-10-200905190-00004; Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum. 1997;40:2187- 98. doi:10.1002/1529-0131(199712)40:123.0.CO;2-H; Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for nduction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis. 2012;71:955-60. doi:10.1136/annrheumdis-2011-200477; Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA- associated renal vasculitis. N Engl J Med. 2010;363:211-20. doi:10.1056/NEJMoa0909169; Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA- associated vasculitis. N Engl J Med. 2010;363:221-32. doi:10.1056/NEJMoa0909905; De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:2461-9. doi:10.1002/art.21142; Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum. 2000;43:1836-40. doi:10.1002/1529- 0131(200008)43: 83.0.CO;2-R; Metzler C, Hellmich B, Gause A, et al. Churg Strauss syndrome – successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol. 2004;22(6 Suppl.):S-52-61.; Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data-driven review. Arthritis Rheum. 2010;62:9-21. doi:10.1002/art.25061; Miloslavsky EM, Specks U, Merkel PA, et al. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis Rheum. 2015;67:1629-36. doi:10.1002/art.39104; Klemmer PJ, Chalermskulrat W, Reif MS, et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with Small-Vessel vasculitis. Am J Kidney Dis. 2003;42:1149-53.doi:10.1053/j.ajkd.2003.08.015; Levy JB, Hammad T, Coulthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004;66:1535-40. doi:10.1111/j.1523-1755.2004.00917.x; Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford). 2007;46:1087-91. doi:10.1093/rheumatology/kem029; Stegeman CA, Tervaert JWC, de Jong PE, et al. Trimethoprimsulfamethoxazole (Co- trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med. 1996;335:16-20. doi:10.1056/NEJM199607043350103; Springer J, Nutter B, Langford CA, et al. Granulomatosis with polyangiitis (Wegener's): impact of maintenance therapy duration. Medicine (Baltimore). 2014;93:82-90. doi:10.1097/MD.0000000000000020; Walsh M, Merkel PA, Mahr A, et al. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res (Hoboken). 2010;62:1166-73. doi:10.1002/acr.20176; Pagnoux C, Hogan SL, Chin H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibodyassociated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 2008;58:2908-18. doi:10.1002/art.23800; Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibodyassociated vasculitis. Ann Rheum Dis. 2007;66:605-17. doi:10.1136/ard.2006.062711; Holle JU, Voigt C, Both M, et al. Orbital masses in granulomatosis with polyangiitis are associated with a refractory course and a high burden of local damage. Rheumatology (Oxford). 2013;52:875-82. doi:10.1093/rheumatology/kes382; Pullerits R, Ljevak M, Vikgren J, et al. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)- associated vasculitis: long-term follow-up from a single centre. Scand J Immunol. 2012;76:411-20. doi:10.1111/j.1365-3083.2012.02747.x; Seror R, Pagnoux C, Ruivard M, et al. Treatment strategies and outcome of induction- refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial. Ann Rheum Dis. 2010;69:2125-30. doi:10.1136/ard.2010.131953; Fortin PM, Tejani AM, Bassett K, et al. Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis. Cochrane Database Syst Rev. 2013;1:CD007057. doi:10.1002/14651858.CD007057.pub3; Тomasson G, Grayson PC, Mahr AD, et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis – a meta-analysis. Rheumatology (Oxford). 2012;51:100-9. doi:10.1093/rheumatology/ker280; Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med. 2007;120:643.e9-14. doi:10.1016/j.amjmed.2006.08.016; Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68:1827-32. doi:10.1136/ard.2008.101279; Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40:371-80. doi:10.1002/art.1780400222; Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine. 2011;90:19-27. doi:10.1097/MD.0b013e318205a4c6; De Groot K, Gross WL, Herlyn K, Reinhold-Keller E. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol. 2001;55(1):31-8.; Alberici F, Smith RM, Jones RB, et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford). 2015;54:1153-60. doi:10.1093/rheumatology/keu452; Suppiah R, Judge A, Batra R, et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken). 2011;63:588-96. doi:10.1002/acr.20433

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2332
https://doi.org/10.14412/1995-4484-2017-12-16

THE ONSET OF ANCA-ASSOCIATED SYSTEMIC VASCULITIS MASKING RHEUMATOID ARTHRITIS ; Дебют АНЦА-ассоциированного системного васкулита под маской ревматоидного артрита

Συγγραφείς: N. F. Frolova, L. V. Korsakova, E. S. Stolyarevich, N. O. Nikonorova, T. V. Beketova, Н. Ф. Фролова, Л. В. Корсакова, Е. С. Столяревич, Н. О. Никонорова, Т. В. Бекетова

Πηγή: Rheumatology Science and Practice; Vol 53, No 6 (2015); 653-656 ; Научно-практическая ревматология; Vol 53, No 6 (2015); 653-656 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20156

Θεματικοί όροι: антитела к циклическому цитруллинированному пептиду, antineutrophil cytoplasmic antibodies, microscopic polyangiitis, granulomatosis with polyangiitis, rheumatoid arthritis, anticyclic citrullinated peptide antibodies, антинейтрофильные цитоплазматические антитела, микроскопический полиангиит, гранулематоз с полиангиитом, ревматоидный артрит

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2158/1381; Jennette J, Falk R, Bacon P, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2012;65:1–11. doi:10.1002/art.37715; Savage C, Winearls C, Evans D, et al. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med. 1985;56:467–83.; Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42:421–30. doi:10.1002/1529-0131(199904)42:33.0.CO;2-6; Ahn J, Hwang J, Lee J, et al. Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitides in Korea. Rheumatol Int. 2011;32:2979–86. doi:10.1007/s00296-011-2079-4; Rodgers H, Guthrie J, Brownjohn A, Turney J. Microscopic polyarteritis: clinical features and treatment. Postgrad Med J. 1989;65:515–8. doi:10.1136/pgmj.65.766.515; Pagnoux C, Seror R, Berezne A, et al. Remittent non-destructive polysynovitis in P-ANCA-positive vasculitis patients with anti-CCP antibodies. Joint Bone Spine. 2010;77(6):604–7. doi:10.1016/j.jbspin.2010.02.013; Бекетова ТВ. Микроскопический полиангиит, ассоциированный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения. Терапевтический архив. 2015;(5):33–46 [Beketova TV. Microscopic polyangiitis associated with anti-neutrophil cytoplasmic antibody: clinical features. Terapevticheskii arkhiv. 2015;(5):33–46 (In Russ.)].; Бекетова ТВ. Гранулематоз с полиангиитом, патогенетически связанный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения. Научно-практическая ревматология. 2012;50(6):19–28 [Beketova TV. Granulomatosis with polyangiitis, which is pathogenetically associated with antineutrophil cytoplasmic antibodies: clinical features. Nauchno-prakticheskaya revmatologiya =Rheumatology Science and Practice. 2012;50(6):19–28 (In Russ.)].; Noritake D, Weiner S, Bassett L, et al. Rheumatic manifestations of Wegener’s granulomatosis. J Rheumatol. 1987;4(5):949–51.; Tervaert JWC, Damoiseaux J, Boomsma MM, Stegeman CA. Absence of anti-cyclic citrullinated peptide antibodies in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2002;46:849–50. doi:10.1002/art.10087; Elkayam O, Segal R, Lidgi M, et al. Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis. Ann Rheum Dis. 2006;65:1110–2. doi:10.1136/ard.2005.045229; Singh S, Singh U, Kunwar А, Chaurasia N. Anti CCP antibody assay: a diagnostic dilemma in diagnosis of tubercular synovitis. World J Pathol. 2014;3:38–44.; Бадокин ВВ, Трошкина ИА, Александрова ЕН. Ревматоидный фактор и антитела к циклическому цитруллинированному пептиду у больных с псориатическим артритом. Научно-практическая ревматология. 2011;(5):32–7 [Badokin VV, Troshkina IA, Alexandrova EN. Rheumatoid factor and anti-cyclic citrullinated peptide antibodies in patients with psoriatic arthritis. Nauchno-prakticheskaya revmatologiya =Rheumatology Science and Practice. 2011;(5):32–7 (In Russ.)].; Vannini A, Cheung K, Fusconi M, et al. Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not? Ann Rheum Dis. 2007;66(4):511–6. doi:10.1136/ard.2006.058933; Aletaha D, Neogi T, Silman A, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81. doi:10.1002/art.27584

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2158
https://doi.org/10.14412/1995-4484-2015-633-656

МИКРОСКОПИЧЕСКИЙ ПОЛИАНГИИТ: ОПИСАНИЕ КЛИНИЧЕСКОГО СЛУЧАЯ

Συγγραφείς: СОКОЛОВ К.Н., ТАУБ Г.С., АЛЕКСИНСКИЙ В.С., ТАРАСЕНКО О.А., УРГАНСКИЙ Е.А., СУХОЦКАЯ Т.Н., АНЦУЛЕВИЧ И.Л.

Θεματικοί όροι: КРОВОХАРКАНЬЕ,АНЦА-АССОЦИИРОВАННЫЕ СИСТЕМНЫЕ ВАСКУЛИТЫ,МИКРОСКОПИЧЕСКИЙ ПОЛИАНГИИТ,ГРАНУЛЕМАТОЗ ВЕГЕНЕРА,СИНДРОМ ГУДПАСЧЕРА,ИММУНОЛОГИЧЕСКИЕ МЕТОДЫ ИССЛЕДОВАНИЯ,HEMOPTYSIS,ANCA-ASSOCIATED SYSTEMIC VASCULITIS,MICROSCOPIC POLYANGIITIS,WEGENER'S GRANULOMATOSIS,GOODPASTURE'S SYNDROME,IMMUNOLOGICAL METHODS

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/mikroskopicheskiy-poliangiit-opisanie-klinicheskogo-sluchaya
http://cyberleninka.ru/article_covers/16975348.png

ДЕБЮТ АНЦА-АССОЦИИРОВАННОГО СИСТЕМНОГО ВАСКУЛИТА ПОД МАСКОЙ РЕВМАТОИДНОГО АРТРИТА

Συγγραφείς: ФРОЛОВА Н.Ф., КОРСАКОВА Л.В., СТОЛЯРЕВИЧ Е.С., НИКОНОРОВА Н.О., БЕКЕТОВА ТАТЬЯНА ВАЛЕНТИНОВНА

Θεματικοί όροι: СИСТЕМНЫЙ ВАСКУЛИТ,АНТИНЕЙТРОФИЛЬНЫЕ ЦИТОПЛАЗМАТИЧЕСКИЕ АНТИТЕЛА,МИКРОСКОПИЧЕСКИЙ ПОЛИАНГИИТ,ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ,РЕВМАТОИДНЫЙ АРТРИТ,АНТИТЕЛА К ЦИКЛИЧЕСКОМУ ЦИТРУЛЛИНИРОВАННОМУ ПЕПТИДУ,SYSTEMIC VASCULITIS,ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES,MICROSCOPIC POLYANGIITIS,GRANULOMATOSIS WITH POLYANGIITIS,RHEUMATOID ARTHRITIS,ANTICYCLIC CITRULLINATED PEPTIDE ANTIBODIES

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/debyut-antsa-assotsiirovannogo-sistemnogo-vaskulita-pod-maskoy-revmatoidnogo-artrita
http://cyberleninka.ru/article_covers/17022678.png

RUSSIAN EXPERIENCE WITH USING MONOCLONAL ANTIBODIES TO B-LYMPHOCYTES (RITUXIMAB) IN SYSTEMIC VASCULITIDES ASSOCIATED WITH NEUTROPHIL CYTOPLASMIC ANTIBODIES (PRELIMINARY RESULTS OF THE RUSSIAN REGISTER NORMA) ; Российский опыт применения моноклональных антител к В-лимфоцитам (ритуксимаб) при системных васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами (предварительные результаты российского регистра НОРМА)

Συγγραφείς: T. V. Beketova, E. N. Aleksandrova, T. M. Novoselova, E. G. Sazhina, E. V. Nikolaeva, A. V. Smirnov, V. N. Sorotskaya, E. V. Zemerova, I. F. Nam, N. M. Nikitina, G. S. Arkhangelskaya, Z. R. Bagautdinova, I. N. Dashkov, S. Yu. Chernykh, O. V. Zhirnova, Yu. A. Lushpaeva, L. V. Masneva, I. P. Afanasieva, A. E. Arseniev, I. V. Kondratenko, I. B. Bashkova, S. I. Glukhova, E. L. Nasonov, Т. В. Бекетова, Е. Н. Александрова, Т. М. Новоселова, Е. Г. Сажина, Е. В. Николаева, А. В. Смирнов, В. Н. Сороцкая, Е. В. Земерова, И. Ф. Нам, Н. М. Никитина, Г. С. Архангельская, З. Р. Багаутдинова, И. Н. Дашков, С. Ю. Черных, О. В. Жирнова, Ю. А. Лушпаева, Л. В. Маснева, И. П. Афанасьева, А. Е. Арсеньев, И. В. Кондратенко, И. Б. Башкова, С. И. Глухова, Е. Л. Насонов

Πηγή: Rheumatology Science and Practice; Vol 52, No 2 (2014); 147-158 ; Научно-практическая ревматология; Vol 52, No 2 (2014); 147-158 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20142

Θεματικοί όροι: Wegener's granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrom), biological anti-B cell therapy, rituximab, гранулематоз с полиангиитом Вегенера, микроскопический полиангиит, эозинофильный гранулематоз с поли- ангиитом Черджа–Строс, биологическая анти-В-клеточная терапия

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1918/1190; Jones R, Cohen Tervaert J, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20. DOI:10.1056/NEJMoa0909169.; Stone J, Merkel P, Spiera R, et al.; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vas- culitis. N Engl J Med. 2010;363(3):221–32. DOI:10.1056/NEJMoa0909905.; Luqmani R, Bacon P, Moots R, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87(11):671–8.; Hellmich B, Flossman O, Gross WL, et al. EULAR recommenda- tions for conducting clinical studies and/or clinical trials in sys- temic vasculitis: focus on anti-neutrophil cytoplasm antibody- associated vasculitis. Ann Rheum Dis. 2007;66(5):605–17. DOI: http://dx.doi.org/10.1136/ard.2006.062711Epub 2006 Dec 14.; Leavitt RY, Fauci A, Block D, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990;33(8):1101–7. DOI: http://dx.doi.org/10.1002/art.1780330807.; Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11. DOI:10.1002/art.37715.; Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094–100. DOI: http://dx.doi.org/10.1002/art.1780330806.; Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculi- tides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011 Jan;90(1):19–27. DOI:10.1097/MD.0b013e318205a4c6.; Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367(3):214–23. DOI: http://dx.doi.org/10.1056/NEJMoa1108735.; Bosch X, Guilabert А, Espinosa G, Mirapeix E. Treatment of anti- neutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA. 2007;298(6):655–69. DOI: http://dx.doi.org/10.1001/jama.298.6.655.; Насонов ЕЛ, редактор. Анти-В-клеточная терапия; в ревматологии: фокус на ритуксимаб. Москва: ИМА-Пресс; 2012. 343 с. [Nasonov EL, editor. Anti-В-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cellular therapy in rheumatology: focus on rituksimab]. Moscow: IMA-Press; 2012. 343 p.]; Specks U, Stone JH; the RAVE-ITN Research Group. Long-term efficacy and safety results of the RAVE trial. Clin Exp Immunol. 2011;164:65.; Jones RB, Walsh M, Jayne DRW, et al. Two-year follow-up results from a randomized trial of RTX versus CyP for ANCA-associated renal vasculitis: RITUXVAS. Clin Exp Immunol. 2011;164:57.; Roll P, Ostermeier E, Haubitz M, et al. Efficacy and safety of rit- uximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). J Rheumatol. 2012;39(11):2153–6. DOI:10.3899/jrheum.120482. Epub 2012 Sep 15.; Charles P, Neel A, Tieulie N, et al. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multi- centre retrospective study on 80 patients. Rheumatology (Oxford). 2014 Mar;53(3):532-9. DOI:10.1093/rheumatology/ket381. Epub 2013 Nov 26.; Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2009;60(7):2156–68. DOI: http://dx.doi.org/10.1002/art.24637.; Holle JU, Dubrau C, Herlyn K, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): com- parison of efficacy in granulomatous versus vasculitic manifesta- tions. Ann Rheum Dis. 2012;71(3):327–33. DOI: http://dx.doi.org/10.1136/ard.2011.153601.; Visentini M, Ludovisi S, Petrarca A, et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryo- globulinemia secondary to hepatitis C virus infection. Autoimmun Rev. 2011;10(11):714–9. DOI: http://dx.doi.org/10.1016/j.autrev.2011.04.033.; Emery P, Mease PJ, Rubbert-Roth A, et al. Retreatment with rit- uximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheuma- toid arthritis: a retrospective pooled analysis. Rheumatology (Oxford). 2011;50(12):2223–32. DOI:10.1093/rheumatology/ker253. Epub 2011 Sep 16.; Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing antineutrophilcytoplasmic antibody- associated vasculitis. Arthritis Rheum. 2012;64(11):3760–9. DOI: http://dx.doi.org/10.1002/art.34583.; treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62(9):2625–32. DOI: http://dx.doi.org/10.1002/art.27555.; Wendt M, Gunnarson I, Bratt J, Bruchfeld A. Rituximab in relaps- ing or refractory ANCA-associated vasculitis: a case series of 16 patients. Scand J Rheumatol. 2012;41(2):116–9. DOI:10.3109/03009742.2011.620573. Epub 2011 Nov 28.; Pullerits R, Ljevakt M, Vikgren J, Bokarewa M. Off-trial evalua- tion of the B cell targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculi- tis: long-term follow-up from a single centre. Scand J Immunol. 2012;76(4):411–20. DOI:10.1111/j.1365-3083.2012.02747.x.; Tesfa D, Ajeganova S, Hä gglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63(8):2209–14. DOI:10.1002/art.30427.; Besada E, Koldingsnes W, Nossent J. Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center. QJM. 2012;105(6):545–50. DOI: http://dx.doi.org/10.1093/qjmed/hcs015.; Мухин НА, Новиков ПИ, Моисеев СВ и др. Оценка краткосрочной эффективности и безопасности биологических препаратов при различных ревматических заболеваниях – опыт многопрофильного терапевтического стационара. Научно-практическая ревматология. 2013;51(2):138–44. [Mukhin NA, Novikov PI, Moiseev SV, et al. Evaluation of the short-term efficacy and safety of biological agents in different rheumatic diseases: a multidisciplinary thera- peutic hospital’s experience. Nauchno-prakticheskaya revma- tologiya = Rheumatology Science and Practice. 2013;51(2):138–44. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2013-; Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance ther- 640.; apy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol. 2010;5(8):1394–400. DOI: http://dx.doi.org/10.2215/CJN.08821209.; Besada E, Koldingsnes W, Nossent JC. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in gran- ulomatosis with polyangiitis: results from a single centre. Rheumatology (Oxford). 2013;52(11):2041–7. DOI: http://dx.doi.org/10.1093/rheumatology/ket257.; Kartin-Seba R, Goldbin J, Keoch KA, et al. Rituximab for emmission, induction and maintenance in ANCA-associated vas- culitis: a single centered 10-year experience in 108 patients. Arthritis Rheum. 2010;62 Suppl 10:680.; Roubaud-Baudron C, Pagnoux C, Meaux-Ruault N, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol. 2012;39(1):125–30. DOI: http://dx.doi.org/10.3899/jrheum.110143.; Available from: http://www.nice.org.uk/nicemedia/live/13960/65382/65382.pdf; Gregersen JW, Chaudhry A, Jayne DR. Rituximab for ANCA- associated vasculitis in the setting of severe infection. Scand J Rheumatol. 2013;42(3):207–10. DOI: http://dx.doi.org/10.3109/03009742.2012.739638.; Van Oers MH, van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non- Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853–8. DOI:10.1200/JCO.2009.26.5827. Epub 2010 May 3.; Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of patients receiving rituximab in rheumatoid arthritis clini- cal trials. J Rheumatol. 2010;37(3):558–67. DOI:10.3899/jrheum.090856. Epub 2010 Jan 28.; Gottenberg JE, Ravaud P, Bardin T, et al.; AutoImmunity and Rituximab registry and French Society of Rheumatology. Risk fac- tors for severe infections in patients with rheumatoid arthritis; Kaushik VV, Reddy HV, Bucknall RC. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis. 2006;65(8):1116–7. DOI: http://dx.doi.org/10.1136/ard.2005.047308.; Donvik KK, Omdal R. Churg-Strauss syndrome successfully treat- ed with rituximab. Rheumatol Int. 2010;31(1):89–91. DOI:10.1007/s00296-009-1146-6. Epub 2009 Sep 30.; Saech J, Owczarczyk K, Owczarzyk K, et al. Successful use of rit- uximab in a patient with Churg-Strauss syndrome and refractory central nervous system involvement. Ann Rheum Dis. 2010;69(6):1254–5. DOI:10.1136/ard.2009.109850. Epub 2009 Sep 9.; Cartin-Ceba R, Keogh KA, Specks U, et al. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant. 2011;26(9):2865–71. DOI:10.1093/ndt/gfq852. Epub 2011 Feb 16.; Pepper RJ, Fabre MA, Pavesio C, et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associ- ated with diminished T-cell interleukin-5 production. Rheumatology (Oxford). 2008;47(7):1104–5. DOI:10.1093/rheumatology/ken175. Epub 2008 May 20.; Thiel J, Hä ssler F, Salzer U, et al. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangi- itis (Churg-Strauss syndrome). Arthritis Res Ther. 2013;15(5):R133. DOI:10.1186/ar4313.; Bouldouyre M-A, Cohen P, Guillevin L. Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome. Ann Rheum Dis. 2009;68(4):606. DOI:10.1136/ard.2008.093773.; Malm IJ, Mener DJ, Kim J, et al. Otolaryngological progression of granulomatosis with polyangiitis after systemic treatment with rituximab. Otolaryngol Head Neck Surg. 2014 Jan;150(1):68–72. DOI:10.1177/0194599813509784. Epub 2013 Oct 23.; Knight A, Hallenberg H, Baecklund E. Efficacy and safety of rit- uximab as maintenance therapy for relapsing granulomatosis with polyangiitis – a case series. Clin Rheumatol. 2013 Aug 20. DOI:10.1007/s10067-013-2351-y.

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/1918
https://doi.org/10.14412/1995-4484-2014-147-158

РОССИЙСКИЙ ОПЫТ ПРИМЕНЕНИЯ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К В-ЛИМФОЦИТАМ (РИТУКСИМАБ) ПРИ СИСТЕМНЫХ ВАСКУЛИТАХ, АССОЦИИРОВАННЫХ С АНТИНЕЙТРОФИЛЬНЫМИ ЦИТОПЛАЗМАТИЧЕСКИМИ АНТИТЕЛАМИ (ПРЕДВАРИТЕЛЬНЫЕ РЕЗУЛЬТАТЫ РОССИЙСКОГО РЕГИСТРА НОРМА)

Συγγραφείς: Бекетова, Татьяна, Александрова, Е., Новоселова, Т., Сажина, Е., Николаева, Е., Сороцкая, В., Земерова, Е., Нам, И., Никитина, Н., Архангельская, Г., Багаутдинова, З., Дашков, И., Черных, С., Жирова, О., Лушпаева, Ю., Маснева, Л., Афанасьева, И., Арсеньев, А., Кондратенко, И., Башкова, И., Глухова, С., Насонов, Е., Смирнов, А.

Θεματικοί όροι: СИСТЕМНЫЙ ВАСКУЛИТ, АССОЦИИРОВАННЫЙ С АНТИНЕЙТРОФИЛЬНЫМИ ЦИТОПЛАЗМАТИЧЕСКИМИ АНТИТЕЛАМИ, ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ ВЕГЕНЕРА, МИКРОСКОПИЧЕСКИЙ ПОЛИАНГИИТ, ЭОЗИНОФИЛЬНЫЙ ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ ЧЕРДЖА-СТРОС, БИОЛОГИЧЕСКАЯ АНТИ-В-КЛЕТОЧНАЯ ТЕРАПИЯ, РИТУКСИМАБ, WEGENER''S GRANULOMATOSIS WITH POLYANGIITIS, EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS SYNDROM)

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/rossiyskiy-opyt-primeneniya-monoklonalnyh-antitel-k-v-limfotsitam-rituksimab-pri-sistemnyh-vaskulitah-assotsiirovannyh-s
http://cyberleninka.ru/article_covers/15616969.png

МИКРОСКОПИЧЕСКИЙ ПОЛИАНГИИТ: ОПИСАНИЕ КЛИНИЧЕСКОГО СЛУЧАЯ

Πηγή: Журнал Гродненского государственного медицинского университета.

Θεματικοί όροι: КРОВОХАРКАНЬЕ,АНЦА-АССОЦИИРОВАННЫЕ СИСТЕМНЫЕ ВАСКУЛИТЫ,МИКРОСКОПИЧЕСКИЙ ПОЛИАНГИИТ,ГРАНУЛЕМАТОЗ ВЕГЕНЕРА,СИНДРОМ ГУДПАСЧЕРА,ИММУНОЛОГИЧЕСКИЕ МЕТОДЫ ИССЛЕДОВАНИЯ,HEMOPTYSIS,ANCA-ASSOCIATED SYSTEMIC VASCULITIS,MICROSCOPIC POLYANGIITIS,WEGENER'S GRANULOMATOSIS,GOODPASTURE'S SYNDROME,IMMUNOLOGICAL METHODS, 3. Good health

Περιγραφή αρχείου: text/html

Σύνδεσμος πρόσβασης: http://cyberleninka.ru/article/n/mikroskopicheskiy-poliangiit-opisanie-klinicheskogo-sluchaya
http://cyberleninka.ru/article_covers/16975348.png

ДЕБЮТ АНЦА-АССОЦИИРОВАННОГО СИСТЕМНОГО ВАСКУЛИТА ПОД МАСКОЙ РЕВМАТОИДНОГО АРТРИТА

Πηγή: Научно-практическая ревматология.

Θεματικοί όροι: СИСТЕМНЫЙ ВАСКУЛИТ,АНТИНЕЙТРОФИЛЬНЫЕ ЦИТОПЛАЗМАТИЧЕСКИЕ АНТИТЕЛА,МИКРОСКОПИЧЕСКИЙ ПОЛИАНГИИТ,ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ,РЕВМАТОИДНЫЙ АРТРИТ,АНТИТЕЛА К ЦИКЛИЧЕСКОМУ ЦИТРУЛЛИНИРОВАННОМУ ПЕПТИДУ,SYSTEMIC VASCULITIS,ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES,MICROSCOPIC POLYANGIITIS,GRANULOMATOSIS WITH POLYANGIITIS,RHEUMATOID ARTHRITIS,ANTICYCLIC CITRULLINATED PEPTIDE ANTIBODIES, 3. Good health

Περιγραφή αρχείου: text/html

Σύνδεσμος πρόσβασης: http://cyberleninka.ru/article/n/debyut-antsa-assotsiirovannogo-sistemnogo-vaskulita-pod-maskoy-revmatoidnogo-artrita
http://cyberleninka.ru/article_covers/17022678.png

Российский опыт применения моноклональных антител к В-лимфоцитам (ритуксимаб) при системных васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами (предварительные результаты российского регистра норма)

Πηγή: Научно-практическая ревматология.

Θεματικοί όροι: СИСТЕМНЫЙ ВАСКУЛИТ, АССОЦИИРОВАННЫЙ С АНТИНЕЙТРОФИЛЬНЫМИ ЦИТОПЛАЗМАТИЧЕСКИМИ АНТИТЕЛАМИ, ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ ВЕГЕНЕРА, МИКРОСКОПИЧЕСКИЙ ПОЛИАНГИИТ, ЭОЗИНОФИЛЬНЫЙ ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ ЧЕРДЖА-СТРОС, БИОЛОГИЧЕСКАЯ АНТИ-В-КЛЕТОЧНАЯ ТЕРАПИЯ, РИТУКСИМАБ, WEGENER'S GRANULOMATOSIS WITH POLYANGIITIS, EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS SYNDROM), 3. Good health

Περιγραφή αρχείου: text/html

Σύνδεσμος πρόσβασης: http://cyberleninka.ru/article/n/rossiyskiy-opyt-primeneniya-monoklonalnyh-antitel-k-v-limfotsitam-rituksimab-pri-sistemnyh-vaskulitah-assotsiirovannyh-s
http://cyberleninka.ru/article_covers/15616969.png

Структурно-метаболические особенности эритроцитов у больных системными васкулитами

Πηγή: Научно-практическая ревматология.

Θεματικοί όροι: МИКРОСКОПИЧЕСКИЙ ПОЛИАНГИИТ, ДИССЕМИНИРОВАННОЕ ВНУТРИСОСУДИСТОЕ СВЕРТЫВАНИЕ, ЭРИТРОЦИТ, ПУРПУРА ГЕНОХА-ШЕНЛЕЙНА, HENOCH-SCHONLEIN PURPURA (HSP), MICROSCOPIC POLYANGIIIIS (MPA), DISSEMINATED INTRAVASCULAR COAGULATION (DIC)

Περιγραφή αρχείου: text/html

Σύνδεσμος πρόσβασης: http://cyberleninka.ru/article/n/strukturno-metabolicheskie-osobennosti-eritrotsitov-u-bolnyh-sistemnymi-vaskulitami
http://cyberleninka.ru/article_covers/14437046.png